Screening with biomarkers for the early detection of AD
Research type
Research Study
Full title
PREDICTOM: Evaluation and Validation of a Biomarker Screening Platform to Identify Risk of Alzheimer’s Disease at Point of Care
IRAS ID
339758
Contact name
Dag Aarsland
Contact email
Sponsor organisation
Helse Stavanger HF (Stavanger University Hospital)
Duration of Study in the UK
4 years, 0 months, days
Research summary
4,000 participants from several countries will take part in PREDICTOM. Biological samples such as saliva, stool and blood via finger pricks are taken either at home by the participants themselves or at GPs. The project participants will also complete online tests of memory function in addition to biological samples collection in first level (Cohort 1), they are sent for analysis in laboratories. Artificial intelligence technology is then used to analyse the results. In second level, 615 participants selected from Cohort 1 on the basis of biomarker results indicating high (n=415) or low (n=200) risk of AD or related disorder. Participants will undergo more comprehensive biomarker collection in a clinic setting (Level 2: EEG, blood, hearing, MRI) followed by a final diagnostic evaluation to confirm or rule out a diagnosis of AD using established biomarkers (CSF, plasma, and amyloid PET (Level 3)) in accordance with the most recent National Institute on Aging-Alzheimer’s Association (NIA-AA) criteria
The aim is to develop methods that can detect the disease before the symptoms appear.
New medicines that protect brain cells against Alzheimer's disease will probably become available in 2024, which makes the project particularly relevant. Early detection of dementia is therefore important to slow the progression.REC name
Wales REC 4
REC reference
24/WA/0069
Date of REC Opinion
14 Aug 2024
REC opinion
Further Information Favourable Opinion